The Cigna Group reported third quarter 2026 results that exceeded analyst expectations on both the top and bottom lines. Growth was supported by premium rate increases in the Cigna Healthcare segment and strong organic performance in specialty pharmacy services, which offset lower contributions from the pharmacy benefit division. Following the strong performance, management raised its full-year 2026 adjusted EPS guidance to at least $30.60.
Key Highlights
- Adjusted EPS of $7.98 beat the consensus estimate of $7.46, representing a marginal increase over the prior-year period.
- Total revenue grew 6% year-over-year to $73.7 billion, slightly ahead of the $73.53 billion expected by analysts.
- The Medical Care Ratio (MCR) was 85.0% for the quarter, outperforming the 85.13% estimate, as premium rate adjustments helped manage rising medical utilization costs.
- Cigna Healthcare adjusted pre-tax income rose 15% to $1.2 billion, driven by improved operating efficiencies and higher net investment income.
- Total medical customers reached 18.5 million, a 2% increase since December 31, 2025, led by growth in the Middle and Select markets.